Cover Image
市場調查報告書

同合子家族性高膽固醇血症 (HoFH) :開發中產品分析

Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361615
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
同合子家族性高膽固醇血症 (HoFH) :開發中產品分析 Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 69 Pages
簡介

同合子家族性高膽固醇血症 (HoFH)是由於雙親的突變引起的遺傳性疾病。HoFH會導致LDL膽固醇水平非常高。症狀包括黃斑瘤,胸部疼痛,腳趾不癒合以及腳尖疼痛,胸痛和瘡。治療包括改變飲食和使用Statin系藥物。

本報告提供同合子家族性高膽固醇血症 (HoFH) 的治療藥開發情形調查分析,提供開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

同合子家族性高膽固醇血症 (HoFH)概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

同合子家族性高膽固醇血症 (HoFH的)開發治療藥的企業

  • CymaBay Therapeutics Inc
  • Daewoong Co Ltd
  • Gemphire Therapeutics Inc
  • LipimetiX Development Inc
  • Regeneron Pharmaceuticals Inc
  • RegenxBio Inc
  • The Medicines Company

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9361IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2017, provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape.

Homozygous familial hypercholesterolemia is a genetic disorder which is caused due to mutation from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain and sores on the toes that do not heal. Treatment includes diet changes and statin drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 7, 1, 3 and 1 respectively.

Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Homozygous Familial Hypercholesterolemia (HoFH) - Overview
    • Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development
    • CymaBay Therapeutics Inc
    • Daewoong Co Ltd
    • Gemphire Therapeutics Inc
    • LipimetiX Development Inc
    • Regeneron Pharmaceuticals Inc
    • RegenxBio Inc
    • The Medicines Company
  • Homozygous Familial Hypercholesterolemia (HoFH) - Drug Profiles
    • AEM-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2802 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2814 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alirocumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • evinacumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gemcabene calcium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inclisiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGL-3196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGL-3745 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGX-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seladelpar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects
  • Homozygous Familial Hypercholesterolemia (HoFH) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 06, 2017: Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia
      • Mar 14, 2017: The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17
      • Jan 30, 2017: Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial
      • Jan 05, 2017: Gemphire Therapeutics Provides Clinical Update
      • Dec 19, 2016: Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study
      • Sep 26, 2016: Gemphire Therapeutics Enrolls First Patient in the COBALT-1 Trial Investigating Gemcabene in Homozygous Familial Hypercholesterolemia
      • May 31, 2016: Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
      • Mar 17, 2016: CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia
      • Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia
      • Mar 25, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by CymaBay Therapeutics Inc, H1 2017
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by Daewoong Co Ltd, H1 2017
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by Gemphire Therapeutics Inc, H1 2017
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by LipimetiX Development Inc, H1 2017
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by RegenxBio Inc, H1 2017
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by The Medicines Company, H1 2017
  • Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top